Codexis

About:

Codexis is a biosciences company applying synthetic chemistry technologies to create improved versions of small molecule therapeutics.

Website: http://www.codexis.com

Twitter/X: CodexisInc

Top Investors: EDBI, Casdin Capital, Innovatus Capital Partners, Pequot Capital, CMEA Capital

Description:

Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis’ technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceutical firms using Codexis’ technology, products and services in their manufacturing process development. Codexis creates its products by applying its CodeEvolver® directed evolution technology platform, which introduces genetic mutations into microorganisms. Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA

Total Funding Amount:

$202M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Redwood City, California, United States

Founded Date:

2002-01-01

Contact Email:

Sales-Pharma(AT)codexis.com

Founders:

Alan Shaw, Gjalt Huisman

Number of Employees:

101-250

Last Funding Date:

2024-02-13

IPO Status:

Public

Industries:

© 2025 bioDAO.ai